Pharmacy Times
Volume 0

In an effort to help seniors impacted by the "doughnut hole," Shire Pharmaceuticals is launching a newMedicare Part D component under the Fosrenol (lanthanum carbonate) At Hand Patient AssistanceProgram.

Shire provides help to patients who have no coverage for Fosrenol under prescription drug benefits,Medicare, Medicaid, or other state-funded programs, by providing the drug free of charge or at a shared(reduced) cost. Now, qualifying patients enrolled in a Medicare Part D program who cannot afford theircopayments or coinsurance, along with those facing the doughnut-hole coverage gap, may receive thedrug at no cost. Patients will receive a monthly supply of Fosrenol through the end of the calendar yearin which they enroll in the program.

Fosrenol is indicated to reduce serum phosphate in patients with end-stage renal disease. For moreinformation about the program, call 866-325-8223.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.